| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $43.8M | -22.6% |
| SG&A Expense | $10.6M | -59.9% |
| Operating Income | -$54.4M | +34.5% |
| Net Income | -$52.7M | +31.9% |
| EPS (Basic) | -$15.28 | -506.3% |
| EPS (Diluted) | -$15.28 | -506.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $110.8M | +300.8% |
| Current Assets | $113.0M | +6.0% |
| Total Assets | $114.9M | +7.0% |
| Current Liabilities | $10.5M | -42.1% |
| Total Liabilities | $11.1M | -41.2% |
| Stockholders' Equity | $103.8M | +17.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$51.1M | +19.7% |
| Capital Expenditures | $52K | -76.5% |
| Investing Cash Flow | $15.9M | +50.9% |
| Financing Cash Flow | $116.1M | +90.8% |
| Free Cash Flow | -$51.2M | +19.9% |